152 related articles for article (PubMed ID: 22940623)
21. Exogenous surfactant replacement: how to deliver it?
Biban P; Chini L; Bonetti P; Sacco F; Zaglia F; Santuz P
Acta Biomed; 2012; 83 Suppl 1():27-32. PubMed ID: 23029874
[TBL] [Abstract][Full Text] [Related]
22. Continuous positive airway pressure and surfactant.
Bohlin K; Jonsson B; Gustafsson AS; Blennow M
Neonatology; 2008; 93(4):309-15. PubMed ID: 18525215
[TBL] [Abstract][Full Text] [Related]
23. The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome.
Gerstmann DR; Minton SD; Stoddard RA; Meredith KS; Monaco F; Bertrand JM; Battisti O; Langhendries JP; Francois A; Clark RH
Pediatrics; 1996 Dec; 98(6 Pt 1):1044-57. PubMed ID: 8951252
[TBL] [Abstract][Full Text] [Related]
24. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit.
Ellyett KM; Broadbent RS; Fawcett ER; Campbell AJ
Pediatr Res; 1996 Jun; 39(6):953-7. PubMed ID: 8725254
[TBL] [Abstract][Full Text] [Related]
25. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group.
Fujiwara T; Konishi M; Chida S; Okuyama K; Ogawa Y; Takeuchi Y; Nishida H; Kito H; Fujimura M; Nakamura H
Pediatrics; 1990 Nov; 86(5):753-64. PubMed ID: 2235230
[TBL] [Abstract][Full Text] [Related]
26. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants].
de Winter JP; Egberts J; de Kleine MJ; van Bel F; Wijnands JB; Guit GL
Ned Tijdschr Geneeskd; 1992 Oct; 136(41):2018-24. PubMed ID: 1407193
[TBL] [Abstract][Full Text] [Related]
27. Surfactant and respiratory distress syndrome.
Milner AD
Turk J Pediatr; 1996; 38(1):37-43. PubMed ID: 8819619
[TBL] [Abstract][Full Text] [Related]
28. [Surfactant treatment of acute pulmonary failure. Other indications than neonatal distress syndrome].
Silberg IE; Grønn M
Tidsskr Nor Laegeforen; 1997 Apr; 117(10):1456-8. PubMed ID: 9198922
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades?
Mugford M
Early Hum Dev; 2006 Feb; 82(2):105-15. PubMed ID: 16457971
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome.
Shapiro DL; Notter RH; Morin FC; Deluga KS; Golub LM; Sinkin RA; Weiss KI; Cox C
Pediatrics; 1985 Oct; 76(4):593-9. PubMed ID: 3900907
[TBL] [Abstract][Full Text] [Related]
31. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
[TBL] [Abstract][Full Text] [Related]
32. A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome.
Horbar JD; Soll RF; Sutherland JM; Kotagal U; Philip AG; Kessler DL; Little GA; Edwards WH; Vidyasagar D; Raju TN
N Engl J Med; 1989 Apr; 320(15):959-65. PubMed ID: 2648150
[TBL] [Abstract][Full Text] [Related]
33. Surfactant and perfluorocarbon aerosolization by means of inhalation catheters for the treatment of respiratory distress syndrome: an in vitro study.
Murgia X; Gastiasoro E; Mielgo V; Alvarez-Diaz F; Lafuente H; Valls-i-Soler A; Gomez-Solaetxe MA; Larrabe JL; Rey-Santano C
J Aerosol Med Pulm Drug Deliv; 2011 Apr; 24(2):81-7. PubMed ID: 21410324
[TBL] [Abstract][Full Text] [Related]
34. [Surfactant replacement therapy with a minimally invasive technique: Experience in a tertiary hospital].
Canals Candela FJ; Vizcaíno Díaz C; Ferrández Berenguer MJ; Serrano Robles MI; Vázquez Gomis C; Quiles Durá JL
An Pediatr (Barc); 2016 Feb; 84(2):79-84. PubMed ID: 26028565
[TBL] [Abstract][Full Text] [Related]
35. Exogenous surfactant: intubated present, nebulized future?
Shah S
World J Pediatr; 2011 Feb; 7(1):11-5. PubMed ID: 20549420
[TBL] [Abstract][Full Text] [Related]
36. Target product profile: aerosolized surfactant for neonatal respiratory distress.
Rao S; Edmond K; Bahl R
Bull World Health Organ; 2023 May; 101(5):341-345. PubMed ID: 37131945
[TBL] [Abstract][Full Text] [Related]
37. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants.
Jorch G; Hartl H; Roth B; Kribs A; Gortner L; Schaible T; Hennecke KH; Poets C
Pediatr Pulmonol; 1997 Sep; 24(3):222-4. PubMed ID: 9330420
[No Abstract] [Full Text] [Related]
38. Catheter and Laryngeal Mask Endotracheal Surfactant Therapy: the CALMEST approach as a novel MIST technique.
Vannozzi I; Ciantelli M; Moscuzza F; Scaramuzzo RT; Panizza D; Sigali E; Boldrini A; Cuttano A
J Matern Fetal Neonatal Med; 2017 Oct; 30(19):2375-2377. PubMed ID: 27780385
[TBL] [Abstract][Full Text] [Related]
39. Surfactant Administration Through Laryngeal or Supraglottic Airways.
Guthrie SO; Fort P; Roberts KD
Neoreviews; 2021 Oct; 22(10):e673-e688. PubMed ID: 34599065
[TBL] [Abstract][Full Text] [Related]
40. Nebulizing poractant alfa versus conventional instillation: Ultrastructural appearance and preservation of surface activity.
Minocchieri S; Knoch S; Schoel WM; Ochs M; Nelle M
Pediatr Pulmonol; 2014 Apr; 49(4):348-56. PubMed ID: 24039226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
